Lives could be saved with hepatitis C treatment

May 17, 2015

In a letter to the Medical Journal of Australia published today, a Monash University-led team is asking for hepatitis C virus patients to gain improved access to drugs to prevent liver related deaths.

Hepatitis C virus (HCV) infection is a major public health burden in Australia, with estimates of 230,000 people chronically infected.

The research team are calling for the government to subsidise a new therapy which has high cure rates, known as direct acting antiviral (DAA) therapy.

Monash University Professor William Sievert said a delay in access to DAA treatment means that thousands of HCV infected patients could die or develop advanced liver disease.

"If we delay just one year, there will be an extra 900 liver related deaths, 800 new cases of cirrhosis and 500 new cases of liver cancer. These staggering numbers double if we wait for two years," he said.

"During this decade, the therapy should become the norm for the HCV-infected population. However, the high cost of DAA regimens and competing public health priorities may limit the potential impact of new HCV therapies."

Currently, the cost of DAA treatment is out of reach for most HCV patients.

"The large number of liver-related deaths every year caused by HCV places an enormous burden on our health system," said Professor Sievert, Department of Medicine at Monash Medical Centre.

"Our research team modelled how the HCV disease burden and associated health care costs in Australia will increase as the infected population ages."

The team demonstrated that increasing the efficacy of antiviral therapy and the number of patients treated could avert the expected increase in HCV liver related deaths and end stage liver disease.

Professor Sievert's team examined the impact of delayed access to DAA treatment by modelling one and two year delays.

"We estimate that if the current treatment regimens continue in Australia, there will be approximately 22,200 liver related deaths between 2014 and 2030," said Professor Sievert.

"However, if DAA treatment is made widely available and accessible through the Pharmaceutical Benefits Scheme (PBS), that number of deaths will decrease to 13,500 in the same time period."

"We believe it is critical to provide patients with access to highly effective treatment to cure HCV infection without delay in order to diminish future HCV-related morbidity and mortality," added Professor Sievert.
-end-


Monash University

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.